OBJECTIVES: International reference pricing (IRP) has increasingly been adapted by multiple countries over the past decades in Europe such as UK, France, Germany, and in Asia such as Taiwan, Korea, Japan, and Singapore. As China’s healthcare reform deepens, the China National Development and Reform Commission has eliminated the traditional cost-based pricing methodology and proposed new pricing strategies be based on market conditions, negotiations, and ability to pay. IRP has become an important component of the considerations. In response, we created an IRP database to facilitate the access of international pricing information.   METHODS: A survey was conducted nationwide to determine referencing countries. A total of ten countries/regions including China, U.S., UK, Germany, France, Canada, Sweden, Japan, South Korean and Taiwan, were identified and included in the database. Based on Chinese commercial databases, top 200 drugs, in terms of selling volume, were identified to be covered. Pricing data for each country were sourced from the official websites released by local authorities. This database is expected to be updated every six months.     RESULTS: An Excel-based database with user-friendly interface was constructed to allow users to accomplish price comparison among different countries/regions right on their desktop. Additionally, conversions between ex-factory price and public price were performed according to local currency and tax rate. Also, multiple search methodologies were instituted to allow users search via branded names, generic names, and ATC codes. Furthermore, a variety of brand names with the identical generic ingredients were identified in different countries/regions. The database also included drug formulation, strength, and pack size in each corresponding country/region. Finally, historical pricing data can be tracked in each country/region for reference and analysis since the launch of database. CONCLUSIONS: The database is the very first database available in China that provides well-organized international pricing reference information based on Chinese market conditions.